Prima Biomed shares are going nuts over a breast cancer treatment

Oli Scarff/Getty Images

Prima Biomed shares jumped more than 25% after European authorities endorsed the further development of a treatment for breast cancer.

The European Medicines Agency (EMA) confirmed its endorsement for a development program of Prima Biomed’s IMP321 treatment.

A planned study is now expected to start in Europe in the 4th quarter of 2015. This is a key step leading to marketing authorisation in the EU.

Frédéric Triebel, Prima’s chief scientific and medical officer, says the EMA’s scientific advice represents a “significant step forward”.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at